Janet Hardy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7720885/publications.pdf

Version: 2024-02-01

		185998	205818
98	2,532	28	48
papers	citations	h-index	g-index
107	107	107	2489
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinical practice guidelines for communicating prognosis and endâ€ofâ€ife issues with adults in the advanced stages of a lifeâ€imiting illness, and their caregivers. Medical Journal of Australia, 2007, 186, S77-S105.	0.8	254
2	Fatigue in patients with cancer. European Journal of Cancer, 1998, 34, 1670-1676.	1.3	217
3	Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Toxicity of Subcutaneous Ketamine in the Management of Cancer Pain. Journal of Clinical Oncology, 2012, 30, 3611-3617.	0.8	189
4	What influences participation in clinical trials in palliative care in a cancer centre?. European Journal of Cancer, 2000, 36, 621-626.	1.3	118
5	A prospective survey of the use of dexamethasone on a palliative care unit. Palliative Medicine, 2001, 15, 3-8.	1.3	111
6	Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction. Journal of Pain and Symptom Management, 2015, 49, 814-821.	0.6	83
7	The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliative Medicine, 1998, 12, 75-82.	1.3	80
8	What do palliative care patients and their relatives think about research in palliative care?—a systematic review. Supportive Care in Cancer, 2010, 18, 905-911.	1.0	80
9	A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24Âmg p.o. with placebo and metoclopramide 10Âmg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Supportive Care in Cancer, 2002, 10, 231-236.	1.0	64
10	Pharmacological options for the management of refractory cancer painâ€"what is the evidence?. Supportive Care in Cancer, 2015, 23, 1473-1481.	1.0	53
11	Treatment of Nausea and Vomiting in Terminally III Cancer Patients. Drugs, 2008, 68, 2575-2590.	4.9	52
12	<i>CYP2B6</i> * <i>6</i> allele and age substantially reduce steadyâ€state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology, 2015, 80, 276-284.	1.1	51
13	The Efficacy of Haloperidol in the Management of Nausea and Vomiting in Patients with Cancer. Journal of Pain and Symptom Management, 2010, 40, 111-116.	0.6	50
14	The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. British Journal of Cancer, 1990, 62, 684-686.	2.9	47
15	Novel consent process for research in dying patients unable to give consent. BMJ: British Medical Journal, 2003, 327, 198-0.	2.4	46
16	Randomised controlled trials of palliative care $\hat{a}\in$ a survey of the views of advanced cancer patients and their relatives. European Journal of Cancer, 2008, 44, 1820-1828.	1.3	43
17	Corticosteroids for the management of cancer-related pain in adults. The Cochrane Library, 2021, 2021, CD010756.	1.5	43
18	The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial. Journal of Pain and Symptom Management, 2015, 50, 289-296.	0.6	40

#	Article	IF	CITATIONS
19	Neuropathic pain in cancer: systematic review, performance of screening tools and analysis of symptom profiles. British Journal of Anaesthesia, 2017, 119, 765-774.	1.5	38
20	Outcome of Malignant Spinal Cord Compression at a Cancer Center. Journal of Pain and Symptom Management, 2000, 19, 257-264.	0.6	35
21	Interventional options for the management of refractory cancer pain—what is the evidence?. Supportive Care in Cancer, 2016, 24, 1429-1438.	1.0	34
22	An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Supportive Care in Cancer, 2005, 13, 715-721.	1.0	33
23	Therapeutic Challenges in Cancer Pain Management: A Systematic Review of Methadone. Journal of Pain and Palliative Care Pharmacotherapy, 2014, 28, 197-205.	0.5	33
24	Opioid addiction and misuse in adult and adolescent patients with cancer. Internal Medicine Journal, 2017, 47, 632-636.	0.5	33
25	Chemoprevention of breast cancer. Breast Cancer Research and Treatment, 1989, 14, 23-31.	1.1	32
26	Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. Palliative Medicine, 2012, 26, 1042-1047.	1.3	31
27	Placebo and Nocebo Effects in Randomized Controlled Trials: The Implications for Research and Practice. Journal of Pain and Symptom Management, 2013, 46, 722-730.	0.6	31
28	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). BMC Palliative Care, 2019, 18, 110.	0.8	31
29	Using National Health Policies to Improve Access to Palliative Care Medications in the Community. Journal of Pain and Symptom Management, 2009, 37, 395-402.	0.6	30
30	Sedation in terminally ill patients. Lancet, The, 2000, 356, 1866-1867.	6.3	29
31	Planning phase III multi-site clinical trials in palliative care: the role of consecutive cohort audits to identify potential participant populations. Supportive Care in Cancer, 2010, 18, 1571-1579.	1.0	24
32	A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer, 2018, 18, 510.	1.1	22
33	An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care. Journal of Palliative Medicine, 2020, 23, 650-655.	0.6	22
34	Defining Refractory Pain in Cancer for Clinicians and Researchers. Journal of Palliative Medicine, 2012, 15, 5-6.	0.6	21
35	Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials, 2020, 21, 611.	0.7	21
36	Can the LANSS scale be used to classify pain in chronic cancer pain trials? Supportive Care in Cancer, 2013, 21, 3387-3391.	1.0	20

#	Article	IF	CITATIONS
37	Overcoming barriers to evidence-based patient blood management: a restricted review. Implementation Science, 2020, 15, 6.	2.5	20
38	Quantitative determination of the enantiomers of methadone in human plasma and saliva by chiral column chromatography coupled with mass spectrometric detection. Talanta, 2016, 149, 142-148.	2.9	19
39	Consent for trials in palliative care. Lancet, The, 2000, 356, S44.	6.3	16
40	Gatekeeping from palliative care research trials. Progress in Palliative Care, 2008, 16, 167-171.	0.7	16
41	Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer. Clinical Therapeutics, 2015, 37, 2468-2475.	1.1	16
42	Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). Supportive Care in Cancer, 2020, 28, 141-153.	1.0	16
43	Emotionally reflexive labour in end-of-life communication. Social Science and Medicine, 2021, 291, 112928.	1.8	14
44	Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?. Supportive Care in Cancer, 2012, 20, 767-772.	1.0	13
45	A randomised, double-blind controlled trial of intranasal midazolam for the palliation of dyspnoea in patients with life-limiting disease. Supportive Care in Cancer, 2016, 24, 3069-76.	1.0	13
46	Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial. BMJ Open, 2019, 9, e029942.	0.8	13
47	Letter to the editor: Subcutaneous sufentanil for palliative care patients in a hospital setting. Palliative Medicine, 2008, 22, 89-90.	1.3	12
48	Barriers to the Best Care of the Dying in Queensland, Australia. Journal of Palliative Medicine, 2008, 11, 1325-1329.	0.6	12
49	Preliminary Development and Validation of a New End-of-Life Patient-Reported Outcome Measure Assessing the Ability of Patients to Finalise Their Affairs at the End of Life. PLoS ONE, 2014, 9, e94316.	1.1	12
50	Impact of Opioid Therapy on Sleep and Respiratory Patterns in Adults With Advanced Cancer Receiving Palliative Care. Journal of Pain and Symptom Management, 2018, 55, 962-967.	0.6	12
51	An audit of morphine prescribing in a specialist cancer hospital. Palliative Medicine, 1994, 8, 5-10.	1.3	11
52	Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer. Palliative Medicine, 2021, 35, 461-472.	1.3	11
53	Lymphoedema - prevention rather than cure. Annals of Oncology, 1991, 2, 532-533.	0.6	10
54	Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?. Supportive Care in Cancer, 2014, 22, 325-330.	1.0	9

#	Article	IF	Citations
55	Symptom Clusters in Men With Castrate-Resistant Prostate Cancer. Journal of Pain and Symptom Management, 2017, 54, e1-e3.	0.6	9
56	An open-label pilot study of oral vitamin C as an opioid-sparing agent in patients with chronic pain secondary to cancer. Supportive Care in Cancer, 2017, 25, 341-343.	1.0	9
57	Preoperative Anemia and Iron Deficiency Screening, Evaluation and Management: Barrier Identification and Implementation Strategy Mapping. Journal of Multidisciplinary Healthcare, 2020, Volume 13, 1759-1770.	1.1	8
58	Attitudes of Patients with Advanced Cancer Toward Research. Journal of Pain and Symptom Management, 2009, 38, e5-e6.	0.6	7
59	Potential economic impact on hospitalisations of the Palliative Care Clinical Studies Collaborative (PaCCSC) ketamine randomised controlled trial. Australian Health Review, 2016, 40, 100.	0.5	7
60	Prevalence of QTc Prolongation in Patients With Advanced Cancer Receiving Palliative Care—A Cause for Concern?. Journal of Pain and Symptom Management, 2020, 59, 856-863.	0.6	7
61	<p>Preoperative Anemia Screening and Treatment Practices in Patients Having Total Joint Replacement Surgery: A Retrospective, Observational Audit</p> . Journal of Blood Medicine, 2020, Volume 11, 259-265.	0.7	7
62	Palliation of nausea and vomiting. , 2015, , 661-674.		7
63	Can Saliva and Plasma Methadone Concentrations Be Used for Enantioselective Pharmacokinetic and Pharmacodynamic Studies in Patients With Advanced Cancer?. Clinical Therapeutics, 2017, 39, 1840-1848.	1.1	6
64	Assessing transfusion practice in elective surgical patients: a baseline audit. ISBT Science Series, 2019, 14, 415-422.	1.1	6
65	Central Sleep Apnea in Cancer Patients on Opioids. Journal of Pain and Symptom Management, 2010, 40, e3-e5.	0.6	5
66	Reply to K. Jackson et al and W. Leppert. Journal of Clinical Oncology, 2013, 31, 1375-1376.	0.8	5
67	Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management. Journal of Clinical Pharmacology, 2016, 56, 705-713.	1.0	5
68	Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?. Current Treatment Options in Oncology, 2022, 23, 514-525.	1.3	5
69	Integration of oncology and palliative care: setting a benchmark. Supportive Care in Cancer, 2017, 25, 3253-3259.	1.0	4
70	Quality use of medicines: Oral corticosteroids in advanced cancer. Palliative Medicine, 2019, 33, 1325-1326.	1.3	4
71	Harms From Haloperidol for Symptom Management in Palliative Care—a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies. Journal of Pain and Symptom Management, 2019, 58, e6-e8.	0.6	4
72	Acetaminophen in Cancer Pain. Journal of Clinical Oncology, 2005, 23, 1586-1586.	0.8	3

#	Article	IF	Citations
73	Creating a palliative care research network in Queensland, Australia $\hat{a} \in \hat{a}$ is this the answer?. Progress in Palliative Care, 2005, 13, 277-281.	0.7	3
74	Progressing an Evidence-Base Beyond Case Series. Journal of Palliative Medicine, 2011, 14, 1283-1283.	0.6	3
75	Validation of a Fentanyl Transdermal Adhesion Scoring Tool for Use in Clinical Practice. Journal of Pain and Symptom Management, 2015, 49, 934-938.	0.6	3
76	Corticosteroids as Co-analgesics With Opioids for Cancer-Related Pain: A Feasibility Study. Journal of Pain and Symptom Management, 2017, 54, e1-e2.	0.6	3
77	The lipophilic opioids: fentanyl, alfentanil, sufentanil, and remifentanil. , 2009, , 175-192.		3
78	Economic evaluation of the randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of chronic cancer pain. Palliative Medicine, 2019, 33, 74-81.	1.3	2
79	Stringent Control of Opioids: Sound Public Health Measures, but a Step Too Far in Palliative Care?. Current Oncology Reports, 2020, 22, 34.	1.8	2
80	The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer. Current Treatment Options in Oncology, 2021, 22, 17.	1.3	2
81	Opioids in the terminal phase. , 2009, , 455-460.		2
82	Diamorphine., 2009,, 263-268.		2
83	Association of polymorphisms in <i>ARRB2</i> and clinical response to methadone for pain in advanced cancer. Pharmacogenomics, 2022, 23, 281-289.	0.6	2
84	Can transdermal fentanyl cause diarrhea?. Journal of Pain and Symptom Management, 1997, 13, 188-189.	0.6	1
85	Insurance cover for research in independent hospices. Palliative Medicine, 2003, 17, 648-649.	1.3	1
86	A Theoretically Informed Approach to Support the Implementation of Pre-Operative Anemia and Iron Deficiency Screening, Evaluation, and Management Pathways: Protocol for a Type Two Hybrid-Effectiveness Study. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 1037-1044.	1.1	1
87	Opioids in renal failure. , 2009, , 69-80.		1
88	Opioid rotation., 2009,, 301-312.		1
89	Palliative medicine in cancer. Lancet, The, 1997, 350, 296.	6.3	0
90	Corerspondence. International Journal of Palliative Nursing, 2000, 6, 358-359.	0.2	0

#	Article	IF	CITATIONS
91	A Review of the COX-2 Inhibitors. Progress in Palliative Care, 2001, 9, 47-52.	0.7	О
92	Palliative care in breast cancer., 2003,, 357-385.		0
93	Is levomepromazine stable over time?. Palliative Medicine, 2011, 25, 284-285.	1.3	О
94	Castrate-resistant prostate cancer: lessons learnt from a pilot study in the palliative care research population. International Journal of Palliative Nursing, 2018, 24, 96-98.	0.2	0
95	Interests and conflicts when writing, reviewing and editing papers on voluntary assisted dying. Internal Medicine Journal, 2021, 51, 1563-1566.	0.5	O
96	Palliative care in paediatric oncology. , 2004, , 684-703.		0
97	Codeine. , 2009, , 81-88.		O
98	Symptom management in the last days of life. , 2011, , 398-404.		0